Deborah Shultz, MD
General Practice · Tampa, FLNPI 1154341014
Payments from drug & device makers
Across 233 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$890
- Amgen$395
- AbbVie$311
- GSK$286
- Merz North America, Inc.$274
- Boehringer Ingelheim$249
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,865100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $890 |
| Amgen(2 entities) | 27 | $395 |
| AbbVie(2 entities) | 20 | $311 |
| GSK | 20 | $286 |
| Merz North America, Inc. | 1 | $274 |
| Boehringer Ingelheim | 16 | $249 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $230 |
| Merck | 16 | $215 |
| Johnson & Johnson | 11 | $178 |
| Astellas Pharma US Inc | 8 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $100 |
| Biohaven Pharmaceuticals, Inc. | 5 | $86 |
| Novo Nordisk | 4 | $85 |
| Amarin Pharma, Inc. | 4 | $71 |
| Pfizer | 4 | $61 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Aytu Biopharma, Inc. | 3 | $42 |
| Abbott | 2 | $36 |
| Lilly USA, LLC | 2 | $30 |
| Eisai Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $22 |
| Bayer | 1 | $22 |
| Medtronic | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Clarus Therapeutics Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$3,880 in reported general payments places this provider in the 90th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 54 | $451 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $402 |
| Gabapentin | 21 | $308 |
| Levothyroxine Sodium | 22 | $217 |
| Cefdinir | 12 | $211 |
| Fluticasone Propionate | 15 | $205 |
| Atorvastatin Calcium | 19 | $166 |
| Omeprazole | 14 | $163 |
| Rosuvastatin Calcium | 21 | $150 |
| Metformin Hcl | 17 | $112 |
| Lisinopril | 22 | $109 |
| Amlodipine Besylate | 15 | $98 |
| Azithromycin | 20 | $76 |
Paid to pharmacies, not to this prescriber.
Other general practice in Tampa
- Arnaldo Orellana MolinaTampa$2.5M
- Robert HannumTampa$1.8M
- Osvanny NodalTampa$1.1M
- Jose CardonaMiami$71M
- Lawrence GalitzMiami Gardens$42.5M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Frank AlvarezHialeah$13.6M
- Hector RodriguezMiami$12.8M
- Eddie ArmasSouth Miami$12.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.